These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 37828561)

  • 1. Glycolysis-cholesterol metabolic axis in immuno-oncology microenvironment: emerging role in immune cells and immunosuppressive signaling.
    Jin J; Zhao Q; Wei Z; Chen K; Su Y; Hu X; Peng X
    Cell Biosci; 2023 Oct; 13(1):189. PubMed ID: 37828561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a personalized classifier to predict the prognosis and response to immunotherapy in glioma based on glycolysis and the tumor microenvironment.
    Fan P; Xia J; Zhou M; Zhuo C; He H
    PeerJ; 2023; 11():e16066. PubMed ID: 37744243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints.
    Xu Y; He L; Fu Q; Hu J
    Front Oncol; 2021; 11():759015. PubMed ID: 34858835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy.
    Xiao C; Tian H; Zheng Y; Yang Z; Li S; Fan T; Xu J; Bai G; Liu J; Deng Z; Li C; He J
    Front Cell Dev Biol; 2022; 10():1013885. PubMed ID: 36200045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic reprogramming in the immunosuppression of tumor-associated macrophages.
    Wang Y; Wang D; Yang L; Zhang Y
    Chin Med J (Engl); 2022 Oct; 135(20):2405-2416. PubMed ID: 36385099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors.
    Gupta S; Dwarakanath BS
    Curr Med Chem; 2020; 27(24):4002-4015. PubMed ID: 29852858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunities.
    Ganapathy-Kanniappan S
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):212-220. PubMed ID: 28400131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Tumor Metabolic Reprogramming in Tumor Immunity.
    Zhang X; Song W; Gao Y; Zhang Y; Zhao Y; Hao S; Ni T
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulating T-cell metabolism to enhance immunotherapy in solid tumor.
    Chen C; Wang Z; Ding Y; Qin Y
    Front Immunol; 2022; 13():1090429. PubMed ID: 36618408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of lipid metabolic reprogramming in tumor microenvironment.
    Yang K; Wang X; Song C; He Z; Wang R; Xu Y; Jiang G; Wan Y; Mei J; Mao W
    Theranostics; 2023; 13(6):1774-1808. PubMed ID: 37064872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates.
    Mohamed E; Al-Khami AA; Rodriguez PC
    Cell Mol Immunol; 2018 May; 15(5):421-427. PubMed ID: 29568118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma.
    Wu S; Kuang H; Ke J; Pi M; Yang DH
    Front Oncol; 2020; 10():591342. PubMed ID: 33520703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment.
    Sasidharan Nair V; Saleh R; Toor SM; Cyprian FS; Elkord E
    Cancer Immunol Immunother; 2021 Aug; 70(8):2103-2121. PubMed ID: 33532902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manipulating Metabolic Alterations and their Consequences to Unleash the Potential of Antitumor Immunotherapy.
    Zhu X; Zhu L; Wu Y
    Curr Protein Pept Sci; 2022; 23(9):585-601. PubMed ID: 35726423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment.
    Zhu Y; Li X; Wang L; Hong X; Yang J
    Front Endocrinol (Lausanne); 2022; 13():988295. PubMed ID: 36046791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the Potential of Glycolytic Modulation in Myeloid-Derived Suppressor Cells for Immunotherapy and Disease Management.
    Kim J; Choi JY; Min H; Hwang KW
    Immune Netw; 2024 Jun; 24(3):e26. PubMed ID: 38974210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment.
    Zhang H; Li S; Wang D; Liu S; Xiao T; Gu W; Yang H; Wang H; Yang M; Chen P
    Biomark Res; 2024 Sep; 12(1):96. PubMed ID: 39227970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy.
    Wegiel B; Vuerich M; Daneshmandi S; Seth P
    Front Oncol; 2018; 8():284. PubMed ID: 30151352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functions of Key Enzymes of Glycolytic Metabolism in Tumor Microenvironment.
    Xu W; Weng J; Xu M; Zhou Q; Liu S; Hu Z; Ren N; Zhou C; Shen Y
    Cell Reprogram; 2023 Jun; 25(3):91-98. PubMed ID: 37172278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.